Skip NavigationSkip to Content
Return Return to Search Results

The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model

  1. Author:
    Higuchi, Takashi
    Kawaguchi, Kei
    Miyake, Kentaro
    Oshiro, Hiromichi
    Zhang, Zhiying
    Razmjooei, Sahar
    Wangsiricharoen, Sintawat
    Igarashi, Kentaro
    Yamamoto, Norio
    Hayashi, Katsuhiro
    Kimura, Hiroaki
    Miwa, Shinji
    Nelson, Scott D
    Dry, Sarah M
    Li, Yunfeng
    Chawla, Sant P
    Eilber, Frederick C
    Singh, Shree Ram
    Tsuchiya, Hiroyuki
    Hoffman, Robert M

  2. Author Address

    AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan., AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA., AntiCancer, Inc., San Diego, CA, USA., Department of Pathology, University of California, Los Angeles, CA, USA., Sarcoma Oncology Center, Santa Monica, CA, USA. Electronic address: santchawla@gmail.com., Division of Surgical Oncology, University of California, Los Angeles, CA, USA., Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. Electronic address: singhshr@mail.nih.gov., Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan. Electronic address: tsuchi@med.kanazawa-u.ac.jp., AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA. Electronic address: all@anticancer.com.,
    1. Year: 2019
    2. Date: Jan 04
    3. Epub Date: 2019 01 04
  2. Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
    1. 111
    2. Pages: 835-840
  4. Type of Article: Article
  5. ISSN: 0753-3322
  1. Abstract:

    Undifferentiated/unclassified soft-tissue sarcomas (USTS) is recalcitrant neoplasms that is usually treated with doxorubicin (DOX)-containing regimens as first-line therapy. Nanoparticle albumin-bound paclitaxel (nab-PTX) is a nanotechnology-based drug and is widely used in pancreatic cancer in combination with gemcitabine (GEM). The major goal of the present study was to determine the efficacy of nab-PTX in combination with GEM, compared to conventional drugs such as docetaxel (DOC), GEM combined with DOC, or first-line drug DOX on a USTS not-otherwise specified (USTS/NOS) from a striated muscle implanted in the right biceps femoris muscle of nude mice to establish a patient-derived orthotopic xenograft (PDOX) model. USTS PDOX models were randomized into six groups: untreated control; DOX; DOC; nab-PTX; GEM combined with DOC; and GEM combined with nab-PTX. Tumor size and body weight were measured. Tumor growth was inhibited to the greatest extent by GEM combined with nab-PTX. Tumors treated with GEM combined with nab-PTX had the most necrosis. Body weight of the treated mice was not significantly different from the untreated controls. The present study demonstrates the power of the PDOX model to identify a novel effective treatment strategy of the combination of GEM and nab-PTX for recalcitrant soft-tissue sarcomas. These results suggest that combination of GEM and nab-PTX could be a promising therapeutic strategy for USTS. Published by Elsevier Masson SAS.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.biopha.2018.12.110
  3. PMID: 30616082
  4. View record in Web of Science®
  5. WOS: 000458737800090
  6. PII : S0753-3322(18)36567-3

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel